10-KPeriod: FY2012

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2012

Filed February 4, 2013For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) in its 2013 10-K filing for the year ended December 30, 2012, reported robust revenue growth of 24% to $2.18 billion, driven by a 25% increase in da Vinci procedures performed globally, reaching approximately 450,000. This growth was fueled by strong performance in U.S. gynecologic and general surgery procedures, as well as international prostatectomies, partially offset by a decline in U.S. prostatectomies due to changes in PSA screening recommendations and disease management. The company continues to see a favorable trend in recurring revenue from instruments, accessories, and service, which now represents 57% of total revenue. This recurring revenue stream is a key indicator of customer stickiness and ongoing system utilization. ISRG also demonstrated strong operational execution with a 26% increase in operating income and a healthy cash flow from operations, ending the year with nearly $3 billion in cash, cash equivalents, and investments. The company continues to invest in research and development to expand its product portfolio, including new instruments and imaging technologies.

Financial Highlights

48 data points
Beta

Revenue

$2.18B

72.1% Gross Margin

Net Income

$656.60M

30.1% Net Margin

EPS (Diluted)

$1.78

Total Assets

$4.06B

Cash & Equivalents

$553.70M

Free Cash Flow

$814.20M

Financial Statements
Beta
Revenue$2.18B
Cost of Revenue$608.50M
Gross Profit$1.57B
R&D Expenses$170.00M
SG&A Expenses$522.20M
Operating Expenses$692.20M
Operating Income$878.10M
Net Income$656.60M
EPS (Basic)$1.83
EPS (Diluted)$1.78
Shares Outstanding (Basic)358.20M
Shares Outstanding (Diluted)369.90M

Key Highlights

  • 1Total revenue increased by 24% to $2.18 billion in 2012.
  • 2Global da Vinci procedures increased by 25% to approximately 450,000 in 2012.
  • 3Recurring revenue (instruments, accessories, and service) grew 27% and represented 57% of total revenue.
  • 4Operating income grew 26% to $878.1 million.
  • 5The company sold 620 da Vinci Surgical Systems in 2012, an increase from 534 in 2011.
  • 6Ended the year with $2.92 billion in cash, cash equivalents, and investments.
  • 7U.S. Prostatectomy (dVP) procedures saw a 15% decline, attributed to changes in PSA screening and non-surgical disease management.

Frequently Asked Questions

The primary driver of revenue growth is the increasing adoption of da Vinci Surgical Systems, leading to a higher volume of da Vinci procedures performed globally. This is further supported by recurring revenue from instruments, accessories, and service contracts.

Intuitive Surgical's strategy focuses on increasing patient value by performing more procedures with less invasiveness and greater efficacy. This includes converting open procedures to da Vinci surgery, facilitating difficult minimally invasive surgeries, and continuously innovating new products and improving existing ones to expand clinical applications.

Key risks include achieving continued market acceptance for da Vinci surgery, economic conditions impacting capital spending by hospitals, competition from established and emerging players, regulatory hurdles for new product introductions, and the potential for adverse results in legal proceedings. A significant challenge noted is the decline in U.S. prostatectomy procedures due to changes in medical guidelines and treatment preferences.

The company sells its products through a direct sales organization in key markets like the U.S. and parts of Europe, and through distributors in other regions. International revenue accounted for 21% of total revenue in 2012, with efforts focused on obtaining regulatory approvals and reimbursement for procedures in markets like Japan.